Novartis to pull Valturna in the US
This article was originally published in Scrip
Novartis is to stop marketing its antihypertensive combination Valturna (aliskiren plus valsartan) in the US from 20 July, it has announced, as the FDA updates the labelling for products containing aliskiren following safety concerns.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.